Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,699,498 protect, and when does it expire?

Patent ► Subscribe protects NEUPRO and is included in one NDA. There has been one Paragraph IV challenge on Neupro.

This patent has thirty patent family members in twenty-two countries.

Summary for Patent: ► Subscribe

Title:	Transdermal therapeutic systems having improved stability and their production
Abstract:	This invention provides for, inter alia, a transdermal therapeutic system comprising at least one therapeutically active substance, which is oxidizable by hydroperoxides, wherein the amount of oxidative degradation of said active substances(s) and the corresponding formation of oxidative degradation products is reduced, which comprises one or more constituents of said transdermal therapeutic system being in contact with said active substance(s), wherein the sum of the peroxide number(s) (PON) of each of said constituents related to their percentage of the whole amount of said constituents as expressed by the formula ##EQU1## where N is the percentage content of the whole amount of said constituents in the TTS, n is the number of said constituents in the TTS, i is the running number PON is the peroxide number of each of the constituents, is not greater than 20.
Inventor(s):	Muller; Walter (Neuwied, DE)
Assignee:	LTS Lohmann Therapie-Systeme AG (Andernach, DE)
Application Number:	09/723,130
Patent Claim Types: see list of patent claims	Use; Formulation; Compound;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	RS	Patent No.	Patent Expiration	Product
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-004	Apr 2, 2012	RX	Yes	No	► Subscribe	► Subscribe	Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-001	May 9, 2007	RX	Yes	Yes	► Subscribe	► Subscribe	Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-005	Apr 2, 2012	RX	Yes	No	► Subscribe	► Subscribe	Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-002	May 9, 2007	RX	Yes	No	► Subscribe	► Subscribe	Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-003	May 9, 2007	RX	Yes	No	► Subscribe	► Subscribe	Y

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	199 57 401	Nov 29, 1999
Germany	100 54 713	Nov 04, 2000

International Patent Family for Patent: ► Subscribe

Country	Document Number	Estimated Expiration
China	1195506	► Subscribe
Czech Republic	295031	► Subscribe
Czech Republic	20021867	► Subscribe
Germany	10054713	► Subscribe
Germany	50003145	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

DrugPatentWatch Database Preview